Stents

This channel includes news and new technology innovations for stents, also called vascular scaffolds. These include coronary stents, carotid stents, peripheral stents, bioresorbable or bioabsorbable stents, and renal stents. News included clinical trial data and new technology advances in stents.

West Hills Hospital & Medical Center Ranked No. 1 in Los Angeles County for Door-to-Balloon Time
News | Stents Bifurcation | January 18, 2018

January 18, 2018 – West Hills Hospital & Medical Center, a full-service acute care...

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell

There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or...

FDA Approves New Indication for NuMed CP Stent System
Technology | Stents Bare Metal | December 14, 2017

December 14, 2017 — The U.S. Food and Drug Administration (FDA) announced clearance for NuMed’s Cheatham Platinum (...

Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017

December 13, 2017 — Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug...

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017

November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting,...

Videos | Stents Bifurcation | November 15, 2017

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at...

News | Stents | November 10, 2017

November 10, 2017 — Cordis, a Cardinal Health company, recently unveiled a comprehensive...

The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017

November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience...

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017

November 8, 2017 – New results from the HARMONEE Japan/U.S. Registration Trial, reported by in a first report...

Videos | Stents Bioresorbable | November 07, 2017

A discussion with Ajay Kirtane, M.D., SM, director of the cardiac catheterization laboratories at New York-...

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017

November 6, 2017 —  The first trial to evaluate the safety of...

Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017

November 6, 2017 — Elderly patients undergoing...

Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting | November 03, 2017

November 3, 2017 — Biotronik's Orsiro...

Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017

November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at...

Double Kissing Crush Two-Stent Technique in Left Main Bifurcation Lesions Demonstrates Lower Target Lesion Failure Rates
News | Stents Bifurcation | November 01, 2017

November 1, 2017 — The double kissing (DK) crush two-stent technique was associated with a lower rate of target...

Overlay Init